Blog
RSS FeedPosted by Michael Wonder on 09 Jun 2016
Cancer drug 'a long time coming'
10 June 2016 - PHARMAC has been accused of leaving melanoma patients in suspense by not telling them earlier when their ...
Posted by Michael Wonder on 09 Jun 2016
Government announces new drug funding, including for advanced melanoma
9 June 2016 - Medicine to treat six diseases, including for advanced melanoma, will be available to New Zealanders. ...
Posted by Michael Wonder on 09 Jun 2016
Health sector feedback helps make the most of Government funding boost
9 June 2016 - PHARMAC is today announcing funding of six new treatments across important areas of health, including major advancements ...
Posted by Michael Wonder on 31 May 2016
New Zealand Pharmaceutical Schedule - 1 June 2016 update
1 June 2016 - The June 2016 update to the New Zealand Pharmaceutical Schedule sees the listing of one new medicine. ...
Posted by Michael Wonder on 26 May 2016
New Zealand budget 2016: extra $2.2 billion pumped into health
26 May 2016 - An extra $2.2 billion will be pumped into health over four years to help cope with an ...
Posted by Michael Wonder on 23 May 2016
Proposal to award sole supply of bortezomib in DHB hospitals
As Velcade is currently the only funded brand of bortezomib, there would be no funded brand change resulting from this ...
Posted by Michael Wonder on 16 May 2016
PHARMAC’s new approach for people with rare disorders
16 May 2016 - A new approach PHARMAC has used for funding medicines for rare disorders is gaining real traction, says ...
Posted by Michael Wonder on 12 May 2016
Decision to list bedaquiline (Sirturo) and siltuximab (Sylvant) for rare disorders
12 May 2016 - PHARMAC is pleased to announce the approval of an agreement with Janssen-Cilag for the listing of bedaquiline ...
Posted by Michael Wonder on 05 May 2016
Request for proposal - supply of anti-vascular endothelial growth factor agents
5 May 2016 - PHARMAC invites proposals for the supply of anti-vascular endothelial growth factor agents in New Zealand. ...
Posted by Michael Wonder on 05 May 2016
Proposal to widen funded access to temozolomide for treatment of neuroendocrine tumours and high grade gliomas
4 May 2016 - As part of PHARMAC’s 2015/16 annual Invitation to Tender, PHARMAC is proposing to widen access to fully-funded ...
Posted by Michael Wonder on 05 May 2016
Proposal to widen access to rituximab to include children with nephrotic syndrome
4 May 2016 - PHARMAC is seeking feedback on a proposal to amend the funding restrictions for rituximab in DHB hospitals. ...
Posted by Michael Wonder on 04 May 2016
'It's a very good start' – funding boost for Pharmac welcomed, but is it enough?
5 May 2016 - A top health expert has praised the Government's multi-million dollar funding boost to its pharmaceutical agency Pharmac, ...
Posted by Michael Wonder on 04 May 2016
Melanoma drug could be funded after boost in funding
4 May 2016 - A new generation melanoma drug is likely to be funded by PHARMAC after a $39 million boost ...
Posted by Michael Wonder on 04 May 2016
$124 million increase over four years for investment in new medicines
4 May 2016 - Medicines New Zealand is pleased that the New Zealand Government has today announced a $124 million increase ...
Posted by Michael Wonder on 04 May 2016
PHARMAC announces exciting opportunities for improved health from $39 million budget boost
4 May 2016 - PHARMAC is today opening consultations on seven new treatments across a wide range of health areas, says ...